Jakarta –
Modern has initiated studies of booster vaccines incorporating formulations designed to fend off variants Omicron with vaccines COVID-19 which has existed.
The first participants in the study have been given an experimental injection in a phase 2 study for the candidate Omicron-specific bivalent booster. This injection incorporates Moderna’s current COVID-19 vaccine.
“We are excited to begin our bivalent booster candidate study that includes both Omicron and vaccine-specific candidates Modern COVID-19. Our mRNA platform allows the speed and flexibility to create bespoke vaccines to target new variants as they arise,” said Moderna CEO Stéphane Bancel. Mint.
“Our goal is to stay ahead of the virus, and we are committed to generating and sharing data with public health authorities as they prepare,” he added.
This study which is a continuation of this previous study will evaluate the immunogenicity, safety, and reactogenicity of specific bivalent booster candidates. Omicron as a single booster dose in adults 18 years of age and older who previously received the vaccine COVID-19 two-dose primary and a booster dose, at least three months ago.
Moderna hopes to enroll 375 participants in the trial, which will be conducted in about 20 locations in the United States. Separately, Moderna is evaluating Omicron-specific booster candidates in a phase 3 study in the UK, in collaboration with the National Institute for Health Research (NIHR).
They want to be able to start dosing with the study’s Omicron-specific bivalent candidate booster soon. Besides Modern, Pfizer Inc. are also studying vaccines that incorporate targeting candidates Omicron with approved vaccines.
Watch Videos “Moderna Vaccine Claims to be Safe for Children 6-11 Years“
[Gambas:Video 20detik]
(rns/afr)
–
